An interventional study of Ephedrine and Phenylephrine in Postpartum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Active, not recruiting at 1 site in Canada. Open to female participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital — 5 open to participants now, 6 under way, none of them phase 3. Postpartum Hemorrhage · Samuel Lunenfeld Research Institute, Mount Sinai Hospital.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 7th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2024, is one of 32 with no phase, and was the 29th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →5 of the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital are open now, in 1 country. Recruiting first, the newest first:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–40 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–45 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 40 across the 32 interventional studies, 102 across the 2 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
5 of the studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05290129Samuel Lunenfeld Research Institute, Mount Sinai HospitalOxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study | 2026-12 |
| NCT06285409Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium | 2026-12 |
| NCT06333340Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT07187544Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT06930391Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn about how medication that is used to help treat low blood pressure during a Cesarean delivery (CD) can cause changes to the uterine muscle tissue and its ability to contract, in patients with Type II and gestational diabetes.
Spinal anesthesia administered during elective CD has been known to cause hypotension (low blood pressure) as a side effect during the procedure, and is prevented by administration of vasopressors (medication to raise blood pressure) by the anesthesiologist after the delivery of the baby. Vasopressors treat hypotension by interacting with receptors on blood vessels that increase blood pressure, which can also cause changes to uterine contractility. Inadequate uterine contraction after CD can expose mothers to postpartum hemorrhage (PPH), with diabetic patients displaying a 2.5-times higher risk of PPH.
It is important to understand how vasopressor(s) might affect the uterine contractility of women with Type II and gestational diabetes. Since medication to contract the uterus is also routinely administered at delivery, it is important to study the effect of these drugs in combination. The purpose of this study is to compare uterine contractility patterns and receptor distribution in women with type II and gestational diabetic and control term pregnant patients with administration of vasopressors. This will be done using small uterine tissue samples taken from the incision site following CD, which will then be used for experiments in the laboratory.
The global prevalence of diabetes has increased drastically over the past 20 years, with 1.5 million new cases each year. The prevalence of Type II diabetes in women of childbearing age has shown the greatest increase, in the United States alone rising from 33% in 1990-1998 to 70% in 2020. Additionally, the worldwide rate of cesarean delivery (CD) follows a similar trend. CD procedures can be both elective and emergent, with the rate of elective CD increasing by 30% in Canada since 2001. Neuraxial anesthesia administered during elective CD has been known to induce hypotension as a side effect, which is then countered by administering vasopressors such as epinephrine, norepinephrine, and phenylephrine that act on adrenergic alpha and beta receptors on smooth muscle tissue. However, since these receptors are expressed on the smooth muscle layer of the uterus called the myometrium, vasopressors can elicit changes in myometrial contractility. Inadequate myometrial contractility during CD can expose the mother to postpartum hemorrhage (PPH) which is a leading cause of maternal mortality worldwide.
Additionally, diabetic women undergoing CD are often obese (BMI > 30 kg/m2) or have macrosomia (larger than average baby), which are independent risk factors for PPH. However, there is still a 2.5-fold increased risk in PPH in Type II diabetic patients, even when adjusted for diabetic-associated obesity. Type II diabetics undergoing elective CD also display a reduced contractile profile (as previously explored through in-vitro calcium signaling), which may contribute to their increased risk of PPH. Current research on myometrial contractility shows that throughout the gestational period, the adrenergic receptor subtypes on the myometrial tissue may transition to more pro-contractile phenotypes, which may react differently to administered vasopressors and thus affect induced contractility during CD. Oxytocin, a uterotonic, is the standard treatment for preventing PPH administered immediately after delivery.
There is currently no literature on the unique effects of vasopressors to manage hypotension in obstetric patients who are diagnosed with Type II and gestational diabetes. The increased risk of PPH at CD seen in type II and Gestational diabetics mothers may be due to differences in adrenergic receptor distribution, which have different affinities to the vasopressors administered. No studies thus far have directly explored the role of vasopressors on myometrial contractions in this patient population.
As the use of a standardized vasopressor dosage becomes more routine during elective CD, it is important to understand how this will affect the myometrial contractility of women with Type II and gestational diabetes. The investigators hypothesize that administration of vasopressors in full term pregnant women with type II and gestational diabetes will cause decreased myometrial contractility compared to healthy controls, and that the diabetic tissue will possess a different adrenergic receptor subtype profile compared to controls.
Aim 1: Investigate the differences in myometrial contractility of type II and gestational diabetic vs. control term pregnant patients with administration of vasopressors
Aim 2: Determine the expression of adrenergic receptor subtypes on myometrium of term pregnant type II and gestational diabetic patients
Aim 3: Investigate the difference in downstream adrenergic pathways proteins in myometrial of type II and gestational diabetics vs control patients with administration of vasopressors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The myometrial samples are bathed in physiological salt solution (PSS) only.
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine.
Drug: Ephedrine
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine.
Drug: Phenylephrine
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine.
Drug: Norepinephrine
The myometrial samples are bathed in physiological salt solution (PSS) and oxytocin.
Drug: Oxytocin
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine and oxytocin..
Drug: Ephedrine · Drug: Oxytocin
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine and oxytocin..
Drug: Phenylephrine · Drug: Oxytocin
The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine and oxytocin..
Drug: Norepinephrine · Drug: Oxytocin
Ephedrine in solution, at applicable concentrations based on literature.
Phenylephrine, at applicable concentrations based on literature.
Norepinephrine, at applicable concentrations based on literature.
Oxytocin, at applicable concentrations based on literature.
Also known as: pitocin
Motility index
Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Amplitude of contraction
The maximum extent of uterine muscle contraction, measured in grams (g). The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Frequency of contraction
The number of contractions in uterine muscle (myometrium) over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.
Time frame: 4 hours
Integrated area under response curve (AUC)
Time frame: 4 hours
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 45 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ephedrine · Phenylephrine · Norepinephrine · Oxytocin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →